Magenta Therapeutics Pauses the P-I/II Study in AML Patients

Share this
Magenta Therapeutics

Magenta Therapeutics Pauses the P-I/II Study in AML Patients


  • The participant from the P-I/II dose-escalation, study dosed MGTA-117 at the Cohort 3 level (0.08 mg/kg) in r/r AML reported death and the company is working to evaluate the totality of available data and next steps for the development of MGTA-117
  • The death was reported due to Gr5 SAE (respiratory failure and cardiac arrest) that could be related to MGTA-117 and has been reported to the US FDA as a Suspected Unexpected Serious Adverse Reaction (SUSAR)
  • MGTA-117, an ADC targeting CD117 receptor and carrying an alpha-amanitin payload to kill cancer cells. It acts as a targeted conditioning therapeutic and reduces/eliminates the need for CT for patients receiving gene therapies or undergoing stem cell transplantation.

Ref: GlobeNewswire | Image: Magenta Therapeutics

Related News:- AC Immune Reports Results of ACI-24.060 in P-Ib/II Trial for the Treatment of Alzheimer’s Disease and Down Syndrome

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions